Peer Review History

Original SubmissionMay 7, 2023
Decision Letter - Antonio Simone Laganà, Editor

PONE-D-23-12341The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection

in the presence of intrapartum fever: A pilot studyPLOS ONE

Dear Dr. Ehrlich,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Jul 06 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Antonio Simone Laganà, M.D., Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

"Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

3. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

Additional Editor Comments:

The reviewers have expressed positive comments regarding your article, raising only few concerns. Considering this point, I invite authors to perform the required minor revisions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Fever during labour is a serious problem, it associates with potential significant poor fetal outcome

therefore your research Is interesting

I would like to ask for minor revisions

Abstract: should it be structured (background, methods..etc)?

Introduction: please improve it letting the reader conscious of the implication of intrapartum intraamniotic infection, that can go up to stillbirth (examples: doi: 10.36129/jog.2022.20 PMID: 17547873)

methods: can you better clarify how did you evaluate the power of this study in terms of numbers of participants

Conclusion is missing or was not required?

pay attention to English (... Acknowladgments)

Reviewer #2: I read with great interest the Manuscript titled “The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study” "PONE-D-23-12341", which falls within the aim of this Journal.

In my honest opinion, the topic is interesting enough to attract the readers’ attention. Methodology is accurate and conclusions are supported by the data analysis. Nevertheless, authors should clarify some point and improve the discussion citing relevant and novel key articles about the topic.

Authors should consider the following recommendations:

- Manuscript should be further revised by a native English speaker

- In the Results section, the Authors have simply reported the p values, from which however it is not possible to deduce the real clinical relevance of the highlighted statistical significance. In order to better understand the obtained results, I suggest reporting not only the p values, but also the corresponding confidence intervals

- The authors have not adequately highlighted the strengths and limitations of their study. I suggest clarifying these points

- Does this manuscript conform the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network guidelines? It would be mandatory to declare about this element

- Was this study registered? I could not find any information about this point

- I suggest to discuss, at least briefly, the risk factors associated with adverse fetal outcomes in pregnancies affected by COVID-19 (authors may refer to: PMID: 32975205; PMID: 36143264).

Reviewer #3: I read with great interest the Manuscript titled " The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study" which falls within the aim of the Journal.

In my opinion, this topic analyzed is interesting enough to attract readers’ attention.

Although the manuscript can be considered already of good quality, I would suggest to take into account the following recommendations:

- I would recommend to add further details to discuss common causes of preterm delivery, such as advanced maternal age as well as infections (authors may refer to: PMID: 25027820; PMID: 34207831).

- I suggest a round of language revision, in order to correct few typos and improve readability.

Because of these reasons, the article should be revised and completed. Considering all these points, I think it could be of interest for the readers and, in my opinion, it deserves the priority to be published after minor revisions.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Silvia Ganduscio

Reviewer #3: Yes: Ilaria Cuccu

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

June 9, 2023

Antonio Simone Laganà, M.D., Ph.D.

Academic Editor

PLOS ONE

Dear Dr. Antonio Simone Laganà,

Ref: Submission PONE-D-23-12341

Re: " The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study "

Thank you for the opportunity to revise and resubmit the above mentioned manuscript. The suggestions that the editors and reviewers offered have been incorporated into the manuscript and we hope it is now deemed appropriate for publication. Below you will find our responses to each comment raised.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response: The manuscript was revised according to the PLOS ONEs style guide.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found.

Response: Thank you, we are happy to share the minimal data set after identifying information has been removed. We have uploaded the data set with the revised submission.

3. Please review your reference list to ensure that it is complete and correct.

Response: The reference list has been reviewed for completeness and updated according to the Vancouver style.

Reviewer Comments:

Reviewer 1

Fever during labour is a serious problem, it associates with potential significant poor fetal outcome

therefore your research Is interesting

I would like to ask for minor revisions

Response: Thank you.

Abstract: should it be structured (background, methods..etc)?

Response: Submission guidelines did not specify a structured abstract.

Introduction: please improve it letting the reader conscious of the implication of intrapartum intraamniotic infection, that can go up to stillbirth (examples: doi: 10.36129/jog.2022.20 PMID: 17547873)

Response: Thank you for this comment. “Complications of IAI include maternal and neonatal sepsis, increased rates of operative vaginal deliveries and cesarean sections and may even result in stillbirth (1,2)” has been added in lines 36-38:

methods: can you better clarify how did you evaluate the power of this study in terms of numbers of participants

Response: As this was a pilot study with an unknown variance, sample size was based on acceptable sample size for pilot studies noted in the literature. We have included this information in the manuscript and added the citation. (Lancaster GA, Dodd S, Williamson PR. Design and analysis of pilot studies: recommendations for good practice. J Eval Clin Pract. 2004 May;10(2):307-12. doi: 10.1111/j..2002.384.doc.x. PMID: 15189396.)

Lines 65-66: “We aimed to recruit 20-30 participants in each of the study groups, as is acceptable in pilot studies with unknown variance (8)”

Conclusion is missing or was not required?

Response: Per the submission guidelines, the conclusion may be included in the discussion section and is the final sentence of the section.

(From the submission guidelines – “These sections may all be separate, or may be combined to create a mixed Results/Discussion section (commonly labelled “Results and Discussion”) or a mixed Discussion/Conclusions section (commonly labelled “Discussion”).”)

pay attention to English (... Acknowladgments)

Response: Thank you. We have corrected the mistake. The manuscript was reviewed and revised by a professional, native English speaker language editor.

Reviewer 2

I read with great interest the Manuscript titled “The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study” "PONE-D-23-12341", which falls within the aim of this Journal.

In my honest opinion, the topic is interesting enough to attract the readers’ attention. Methodology is accurate and conclusions are supported by the data analysis. Nevertheless, authors should clarify some point and improve the discussion citing relevant and novel key articles about the topic.

Response: Thank you.

Authors should consider the following recommendations:

- Manuscript should be further revised by a native English speaker

Response: A professional, native English speaker language editor has reviewed and revised the manuscript.

- In the Results section, the Authors have simply reported the p values, from which however it is not possible to deduce the real clinical relevance of the highlighted statistical significance. In order to better understand the obtained results, I suggest reporting not only the p values, but also the corresponding confidence intervals

Response:

We have reanalysed the data and added to the table the effect size statistic for the various test.

1.Confidence intervals were added to the variables with a normal distribution (body temp at admission, WBC and Granulocytes at admission)

2. Phi (φ) measures the strength of the association of the categorical variables. It was added for variables analysed by the Chi-square (mode of delivery, gender of newborn, Apgar score, positive cultures and placental histopathology suggestive of chorioamnionitis).

3. r represents the effect size for the Mann–Whitney U test calculated by dividing z by the n (number of cases) r = Z/√N and was added for all variables analysed by the Mann–Whitney U test

- The authors have not adequately highlighted the strengths and limitations of their study. I suggest clarifying these points

Response: Thank you for this comment. We have added this information in the discussion in the manuscript.

Lines 128-139:

“This study has a few strengths. While most studies have examined the yield of PCT in the detection of IAI in the preterm period and in cases of preterm premature rupture of membranes (11–13), this study included only term pregnancies during labor. There are many known factors that increase the risk of preterm delivery, such as maternal age (14) and infectious conditions (15), potentially confounding the results of a study examining the yield of APRs. Additionally. This study was a controlled comparative study, lowering the risk of bias.

Limitations of this study include the small number of participants, which may have been too small to detect the value of APRs in the diagnosis of IAI. There is no gold standard for the diagnosis of IAI and thus there is no way to ascertain that all of the IAI group participants did, in fact, have the diagnosis”

- Does this manuscript conform the Enhancing the QUAlity and Transparency Of health Research (EQUATOR) network guidelines? It would be mandatory to declare about this element

Response: “The study is in accordance with the Standard for Reporting Diagnostic Accuracy (STARD), as required by the guidelines for Enhancing the QUAlity and Transparency Of health Research.”

This was added to the manuscript, Lines 68-70.

- Was this study registered? I could not find any information about this point

Response: This study was not registered. All results of samples taken from participants were analyzed at a later period and were not used in treatment management. As there was no intervention in this study it does not qualify as a “clinical study” requiring registration.

- I suggest to discuss, at least briefly, the risk factors associated with adverse fetal outcomes in pregnancies affected by COVID-19 (authors may refer to: PMID: 32975205; PMID: 36143264).

Response: The following was added to lines 54-59 of the manuscript: “This study was designed before the outbreak of the COVID-19 pandemic and recruitment occurred during the pandemic. However, all participants tested negative for COVID-19, in accordance with the Israeli Ministry of Health testing guidelines in place, at the time of enrolment. Clinical and laboratory implications of maternal COVID-19 infection and their effect on neonatal morbidity and mortality were previously described (6,7). ”

Reviewer 3

I read with great interest the Manuscript titled " The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study" which falls within the aim of the Journal.

In my opinion, this topic analyzed is interesting enough to attract readers’ attention.

Response: Thank you

Although the manuscript can be considered already of good quality, I would suggest to take into account the following recommendations:

- I would recommend to add further details to discuss common causes of preterm delivery, such as advanced maternal age as well as infections (authors may refer to: PMID: 25027820; PMID: 34207831).

Response: This study is unique compared to other published studies as it includes term pregnancies only. I have added a discussion regarding preterm birth.

Lines 128-133: “While most studies have examined the yield of PCT in the detection of IAI in the preterm period and in cases of preterm premature rupture of membranes (11–13), this study included only term pregnancies during labor. There are many known factors that increase the risk of preterm delivery, such as maternal age (14) and infectious conditions (15), potentially confounding the results of a study examining the yield of APRs.”

- I suggest a round of language revision, in order to correct few typos and improve readability.

Response: A professional, native English speaker language editor has reviewed and revised the manuscript.

We wish to thank you again for the opportunity to improve and resubmit this manuscript. We sincerely hope that We have sufficiently addressed all the reviewers’ comments and concerns and that it is deemed worthy for publication in PLOS ONE.

Respectfully submitted,

Zvi Ehrlich

Attachments
Attachment
Submitted filename: Response to reviewers (1).docx
Decision Letter - Antonio Simone Laganà, Editor

The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection

in the presence of intrapartum fever: A pilot study

PONE-D-23-12341R1

Dear Dr. Ehrlich,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Antonio Simone Laganà, M.D., Ph.D.

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

The authors performed the required corrections, which were positively evaluated by the reviewers. I am pleased to accept this paper for publication.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear authors thank you for having addressed reviewers comment

congratulations for your paper

Best regards

Reviewer #2: I carefully evaluated the revised version of this manuscript.

Authors have performed the required changes, improving significantly the quality of the paper.

Reviewer #3: I wanted to thank the authors for making the requested changes and thus broadening and clarifying the discussion. I also thank them for correcting the English. Thanks to these modifications the article is much more flowing and clearer and that's why it is deserves the priority to be published

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Silvia Ganduscio

Reviewer #3: No

**********

Formally Accepted
Acceptance Letter - Antonio Simone Laganà, Editor

PONE-D-23-12341R1

The yield of procalcitonin and Interleukin-6 in predicting intraamniotic infection in the presence of intrapartum fever: A pilot study

Dear Dr. Ehrlich:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Antonio Simone Laganà

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .